FTD Clinical Research: International trial network (Milestone 4.P)
Achieved
Timeline Start - End
2020 - 2025Research Implementation Area
Translational Tools, Infrastructure, and CapabilitiesAD-Related Dementias Focus
Create an international FTD clinical trial network.
Success Criteria
- Develop a patient registry for FTD clinical studies and a centralized database for de-identified clinical, genetic and biomarker information.
Summary of Key Accomplishments
In 2019, NIA and the NINDS co-funded the ALLFTD Study, a comprehensive clinical research network that is establishing the natural course of the various forms of FTD and will establish a baseline for clinical trials. In partnership with patient advocacy groups, a patient registry was launched (FTD Disorders Registry) and is fully integrated into the ALLFTD Study. The ALLFTD study also has collaborations with several industry partners developing potential therapies now poised for clinical trials. To increase the inclusion of underrepresented groups, the ALLFTD study has added sites in areas with enriched populations of race and ethnic minorities, is translating study materials into several languages, and conducted focused outreach efforts. ALLFTD is a formal partner with the international FTD Prevention Initiative (FPI).
The key accomplishments summary is current as of July 2022.
Accomplishments/Implementation Activities
Funding Initiatives
- PAR-18-296: Complex Integrated Multi-Component Projects in Aging Research
- NOT-AG-20-043: Administrative Supplements for NIA-VA Mentored Physician-Scientist Award in Alzheimer’s Disease and its Related Dementias (AD/ADRD)